Portal hypertension (PH) drives most of the clinical complications in chronic liver diseases. However, its progression in nonalcoholic steatohepatitis (NASH) and its association with the intestinal microbiota (IM) have been scarcely studied. Our aim was to investigate the role of the IM in the mechanisms leading to PH in early NASH. The experimental design was divided in two stages. In stage 1, Sprague-Dawley rats were fed for 8 weeks a high-fat, high-glucose/fructose diet (HFGFD) or a control diet/water (CD). Representative rats were selected as IM donors for stage 2. In stage 2, additional HFGFD and CD rats underwent intestinal decontamination, followed by IM transplantation with feces from oppositediet donors (heterologous transplant) or autologous fecal transplant (as controls), generating four groups: CDautotransplanted, CD-transplanted, HFGFD-autotransplanted, HFGFD-transplanted. After IM transplantation, the original diet was maintained for 12-14 days until death. HFGFD rats developed obesity, insulin resistance, NASH without fibrosis but with PH, intrahepatic endothelial dysfunction, and IM dysbiosis. In HFGFD rats, transplantation with feces from CD donors caused a significant reduction of PH to levels comparable to CD without significant changes in NASH histology. The reduction in PH was due to a 31% decrease of intrahepatic vascular resistance compared to the HFGFDautotransplanted group (P < 0.05). This effect occurs through restoration of the sensitivity to insulin of the hepatic protein kinase B-dependent endothelial nitric oxide synthase signaling pathway. Conclusion: The IM exerts a direct influence in the development of PH in rats with diet-induced NASH and dysbiosis; PH, insulin resistance, and endothelial dysfunction revert when a healthy IM is restored. (HEPATOLOGY 2018;67:1485-1498 P ortal hypertension (PH) is responsible for most of the clinical complications associated with chronic liver diseases. However, the exact mechanisms leading to the development and progression of PH in the specific context of nonalcoholic steatohepatitis (NASH) are incompletely understood. Obesity and insulin resistance (IR) are known risk factors for the development of NASH, but they
P ortal hypertension (PH) is responsible for most of the clinical complications associated with chronic liver diseases. However, the exact mechanisms leading to the development and progression of PH in the specific context of nonalcoholic steatohepatitis (NASH) are incompletely understood. Obesity and insulin resistance (IR) are known risk factors for the development of NASH, but they Abbreviations: Akt, protein kinase B; a-SMA, alpha-smooth muscle actin; CD, control diet; CD-Atr, CD-autotransplanted; CD-Tr, CD-transplanted; COL1a1, collagen-a1; eNOS, endothelial nitric oxide synthase; FXR, farnesoid X receptor; HFGFD, high-fat, high-glucose/fructose diet; HFGFD-Atr, HFGFD-autotransplanted; HFGFD-Tr, HFGFD-transplanted; HOMA-IR, homeostasis model assessment of insulin resistance; IM, intestinal microbiota; IR, insulin resistance; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; P-, phosphorylated; PH, portal hypertension; PP, portal pressure. also seem to aggravate the progression of PH. (1, 2) More interestingly, and unlike what happens in other etiologies of liver disease, it is not uncommon for patients in early stages of nonalcoholic fatty liver disease (NAFLD) to develop PH, even in the complete absence of fibrosis. (3, 4) Studies in patients with noncirrhotic NAFLD suggest that this early development of PH is associated with increased IR. (4, 5) Experimental studies have led to the hypothesis that this early development of PH in NAFLD could be determined by nonfibrotic structural (e.g., sinusoidal narrowing by enlarged steatotic hepatocytes) or functional (endothelial dysfunction resulting in sinusoidal vasoconstriction) changes. (6) (7) (8) The exact mechanisms of these observations are yet to be elucidated, and factors other than IR and increased adiposity may play a key role. The intestinal microbiota (IM) has emerged in recent years as a key factor conditioning the development and progression of NAFLD. (9, 10) Proof-of-concept preclinical studies based on experimental manipulation of the IM by fecal transplantation have clearly shown that the gut microbiota independently contributes to the development of diet-induced hepatic steatosis (11) and modulates fibrosis. (12) Regarding PH, studies in germ-free mice suggest that the IM could contribute to experimental PH, (13) but the specific role in fully developed models of human liver disease (including NASH) remains unstudied.
The aim of the present study was to explore the link between the IM and the mechanisms leading to endothelial dysfunction and PH in early NASH. To address this issue, we proceeded in two stages. The first stage focused on the development and characterization of a diet-induced animal model that was able to reproduce the key phenotypic features of these early stages of NASH (namely obesity, IR, intestinal dysbiosis, endothelial dysfunction, and PH). The second stage consisted of a proof-of-concept fecal-transplant experiment to study the role of the IM in the development of endothelial dysfunction and PH in the aforementioned NASH model.
Materials and Methods

ANIMALS AND DIET
Male Sprague-Dawley rats weighting 200-220 g (Charles River Laboratories, L'Arbresle, France) were housed under a 12-hour light/dark cycle at constant temperature and humidity. Animals had ad libitum access to a high-fat high-glucose/fructose diet (HFGFD) or a control diet (CD). The HFGFD consisted of 30% fat (butter, coconut oil, palm oil, beef tallow) with mainly saturated fatty acids (5.73 kcal/g; Ssniff Spezialdi€ aten GmbH, Soest, Germany), supplemented with cholesterol (1 g/kg) and a beverage of glucose/fructose (42 g/L, 45% glucose and 55% fructose). The CD consisted of a grain-based chow with 4% fat (2.89 kcal/g; Teklad 2014; Harlan laboratories, Indianapolis, IN) and tap water. Body weight and food consumption were monitored twice a week.
All For model development and characterization, rats were fed the CD (n 5 6) or the HFGFD (n 5 6) for 8 weeks. Feces were collected at the basal stage and
after dietary intervention, then frozen at -80 C for bacterial preservation. Hemodynamics, blood biochemistry, liver histology, triglyceride content, and molecular pathways were analyzed. Three representative rats from each group were selected as IM donors for stage 2 on the basis of the degree of PH, NASH, and IR and the IM profile. In order to achieve higher homogeneity in the transplantation procedure, feces from the three CD donors, on the one hand, and the HFGFD donors, on the other hand, were pooled to be used for the heterologous transplantation in stage 2.
Stage 2: Effects of IM Transplantation
Two additional groups of rats were fed the CD (n 5 23) or HFGFD (n 5 27) for 8 weeks and then underwent an IM transplant according to the procedure described in the Supporting Information. After IM transplants, CD rats were divided in two subgroups ( Fig. 1 ): one receiving a heterologous transplant with the HFGFD fecal pool from stage 1 donors (CD-Tr, n 5 13) and one, serving as a control for the transplantation procedure, undergoing transplantation with their own fecal pool (autologous fecal transplant, CD-Atr, n 5 10). The same procedure was followed for the HFGFD group: one HFGFD subgroup received a heterologous transplant with CD microbiota from stage 1 donors (HFGFD-Tr, n 5 14) and the other underwent an autologous fecal transplantation (HFGFD-Atr, n 5 13). After the transplantation procedure, animals were maintained on the original diet they were taking before the procedure; i.e., CD-Atr and CD-Tr rats continued with the CD and HFGFD-Atr and HFGFD-Tr continued with the HFGFD for 12-14 days, until death.
The methods followed to perform the hemodynamic measurements, analysis of serum parameters, as well as for western blot, real-time PCR, and 16S ribosomal RNA gene sequencing are described in detail in the Supporting Information. 
HISTOLOGICAL ANALYSES
Liver samples were fixed in 4% formalin, embedded in paraffin, and sectioned in 4-mm-thick slides. Hematoxylin and eosin was used to assess liver parenchyma and picrosirius red to analyze fibrosis. Samples were evaluated by an expert liver pathologist (M.T.S.) blinded to animal interventions and following the NASH Clinical Research Network criteria (Supporting Information).
STATISTICAL ANALYSIS
Frequency variables are presented as n/N (%). Continuous variables are described as mean 6 standard error of the mean and compared by Student t, MannWhitney, or one-way analysis of variance when indicated. A two-sided P value < 0.05 was required for statistical significance. Statistical analyses were performed with the Sigmastat 3.0 package (San Jose, CA).
Statistical analyses for sequence data were carried out in QIIME and in R. To work with normalized data, we analyzed an equal number of sequences from all groups. The Shapiro-Wilk test was used to check the normality of data distribution. The Kruskal-Wallis one-way test of variance was used to compare the mean number of sequences of the groups, at various taxonomic levels. We performed analyses with the nonparametric multivariate analysis of variance called the adonis test, a nonparametric analysis of variance, to test for differences in microbial community composition. A nonparametric Spearman's correlation test was used to calculate possible relationships among microbial genera and variables in biological data. When possible, the analysis provided false discovery rate-corrected P values.
Results
HFGFD-INDUCED OBESITY, IR, NASH, AND PH IN THE ABSENCE OF FIBROSIS
Metabolic, histological, and hemodynamic features were evaluated in order to characterize the model of early NASH induced by diet. Administration of HFGFD for 8 weeks led to a 20% increase in body weight in comparison to CD (P < 0.001, Table 1 ). Fasting glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) were significantly increased in HFGFD compared to CD animals ( Table 1 and Fig. 2A) . Fasting blood concentrations of albumin, creatinine, bilirubin, alanine aminotransferase, aspartate aminotransferase, triglycerides, cholesterol, high-density lipoprotein, and low-density Bar diagrams show the quantification of P-Akt and P-eNOS using glyceraldehyde 3-phosphate dehydrogenase as a loading control and normalized to the CD group. Representative western blots are shown below. Data represent mean 6 standard error of the mean; *P < 0.05 versus CD. (F) Relative mRNA expression of a-SMA and COL1a1 by quantitative RT-PCR, expressed as a log2 ratio. Glyceraldehyde 3-phosphate dehydrogenase was used as an endogenous control, and results were normalized to the CD group. Abbreviations: CD, control diet; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H/E, hematoxylin and eosin; HFGFD, highfat, high-glucose/fructose diet; NAS, NAFLD activity score.
lipoprotein were not significantly altered by the HFGFD (Table 1) . Liver triglyceride content was significantly increased after HFGFD intake ( Fig. 2B) . At 8 weeks, 100% of HFGFD rats developed histological NASH (i.e., concurrence of steatosis, hepatocellular ballooning, and lobular inflammation). The mean NASH activity as measured by the NAFLD activity score was 4.5 6 0.56 in the HFGFD group versus 1 6 0.37 in controls (P < 0.001). However, fibrosis at week 8 was mild or absent (Fig. 2C ). This absence of histologically detectable fibrosis was accompanied at the molecular level by a similar hepatic mRNA expression of collagen-a1 (COL1A1) and alpha smooth muscle actin (a-SMA) in HFGFD animals compared to controls (Fig. 2F) . portal vein ligation (14, 15) (Fig. 2D) . No changes were observed in systemic hemodynamics (Table 1) .
To further characterize the intrahepatic abnormalities that could have led to the PP increase in the absence of fibrosis, we assessed endothelial dysfunction by analyzing protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) phosphorylation. In our model, HFGFD rats showed reduced hepatic levels of phosphorylated (P-) Akt and P-eNOS compared to controls despite higher insulin levels (Fig. 2E) , suggesting the presence of insulin-dependent endothelial dysfunction in these animals.
HFGFD INDUCED MARKED CHANGES IN THE IM
To verify whether the CD and HFGFD groups developed changes in the IM due to the different diets, fecal samples collected at baseline and after 8 weeks of dietary intervention were analyzed by 16S ribosomal RNA gene sequencing. The HFGFD provoked a global reduction of IM diversity in comparison with both baseline and CD (Fig. 3A) . By comparing taxonomic profiles at the phylum level, we observed that the HFGFD was associated with a significant increase in Firmicutes and a significant decrease in Bacteroidetes compared to the CD ( Fig. 3B ; for more detailed data at family and genus level, see Supporting Fig. S1 ). In addition, the microbial composition similarities between samples, analyzed by UniFrac-based principal coordinates analysis, allowed the identification of three different clusters associated to baseline, CD, and HFGFD (Fig. 3C ). Principal coordinates analysis was performed in fecal samples from 8-week CD and HDGFD rats in stages 1 and 2, obtaining the same results (Fig. 3C) .
IM TRANSPLANT INDUCED IM CHANGES IN HFGFD RATS
Once the differences in IM between the CD and HFGFD groups were confirmed, three representative rats of each group were selected as IM donors based on weight, HOMA-IR, and PP (Supporting Table S1 ).
The changes in the IM triggered by the IM transplantations were analyzed by comparing stool samples collected immediately before transplants and 12-14 days after the autologous and heterologous transplants. The IM present in the HFGFD-Tr group (HFGFD rats transplanted with feces from CD rats) was significantly different from that of the HFGFD-Atr group (HFGFD rats receiving an autotransplantation) but also from the microbiome of HFGFD samples collected before intestinal decontamination (Fig. 4A , for more detailed data at the genus level, see Supporting  Fig. S1 ). No differences were found between the HFGFD-Atr and HFGFD groups. In CD rats, the transplant with IM from HFGFD (CD-Tr) did not induce significant changes in the microbiome composition in comparison with CD-Atr or with the microbiome present in CD samples collected before intestinal decontamination (Fig. 4A) . Further analysis of the IM revealed a tight correlation between the abundance of Clostridium and Adlercreutzia and PP; specifically, the reduction of these species was related to PP increase (Fig. 4B,C) , suggesting a protective role.
FECAL TRANSPLANTATION WITH HEALTHY IM NORMALIZES PH BY IMPROVING INTRAHEPATIC VASCULAR RESISTANCE AND ENDOTHELIAL DYSFUNCTION
After IM transplantation, we evaluated IR, NASH histology, and systemic and portal hemodynamics to elucidate the possible role of the IM in the regulation of PH. The main effects of IM transplantation on these parameters are shown in Table 2 and Fig. 5 . As seen, in healthy animals receiving a CD, transplantation with IM from HFGFD donors was not able to induce relevant changes in IR, NASH histology, or portal hemodynamics in the 14-day period between the IM transplant and final analysis. However, the effect of transplantation of a eubiotic IM (from CD donors) to animals with NASH did induce relevant changes, even while maintaining the HFGFD. Transplantation of CD IM to HFGFD animals (HFGFDTr) was associated with a relevant reduction of fasting glycemia and HOMA-IR compared with controls (HFGFD-Atr), although these changes did not reach statistical significance (Table 2 and Fig. 5A ). Nonetheless, HFGFD-Tr animals did show a significant increase of intrahepatic P-Akt levels compared to HFGFD-Atr animals (Fig. 5E) , indicating a restoration of liver insulin sensitivity after the IM transplantation from healthy individuals. Liver triglyceride content was not altered by IM transplants in either the CD or the HFGFD group (Fig. 5B) .
In terms of liver histology, individual histological NASH features and disease activity (as measured by NAFLD activity score) remained unchanged by IM transplantation (Fig. 5C ). Neither histological fibrosis nor hepatic expression of a-SMA and COL1a1 were modified by IM transplantation (Fig. 5F ). Liver expression of relevant inflammatory mediators, such as inducible nitric oxide synthase, nuclear factor jB and tumor necrosis factor alpha, remained unaltered after both dietary intervention and IM transplantation (Supporting Fig. S2 ).
Regarding systemic and portal hemodynamics, transplantation with HFGFD microbiota to CD-fed rats (CD-Tr) did not induce hemodynamic changes Correlation between microbiome composition and PP was evaluated using the Spearman correlation test. A false discovery rate <0.05 was considered statistically significant. Abbreviation: CD, Control diet; Corr., correlation; FDR, false discovery rate; HFGFD, high-fat, high-glucose/fructose diet; n.s., not significant; PC, principal coordinate. when compared to their corresponding controls (CDAtr), suggesting that the IM alone is not able to induce PH in a healthy liver. However, IM transplantation from healthy controls to HFGFD rats that already had NASH was able to significantly reduce PP (compared to their corresponding HFGFD-Atr controls) to levels similar to CD groups (Table 2 and Fig. 5D ), even while maintaining the HFGFD. This change was mainly due to a significant 31% reduction of intrahepatic vascular resistance in HFGFD-Tr animals compared to their corresponding HFGFD-Atr controls (Table 2 ). Other hemodynamic parameters were not altered ( Table 2) .
This reduction of PP and intrahepatic vascular resistance in HFGFD-Tr animals was associated with a significant amelioration of molecular markers of endothelial dysfunction. Intrahepatic levels of P-eNOS were significantly increased after transplantation with a healthy IM to levels comparable to CD controls (Fig.  5E ). This improvement of endothelial dysfunction was associated with a restoration of intrahepatic levels of P-Akt in the HFGFD-Tr group, as shown above (see also Fig. 5E ). In addition, to assess potential mechanisms of transcriptional regulation of eNOS, we studied the expression of Kr€ uppel-like factor 2, considered essential to maintain a functional endothelial phenotype. (16) In our study, HFGFD-Tr rats experienced a significant increase in the hepatic protein expression of Kr€ uppel-like factor 2 compared to their corresponding controls (HFGFD-Atr; Supporting  Fig. S3A ). mRNA expression of eNOS and Kr€ uppellike factor 2 was also assessed, but no differences were observed between groups (Supporting Fig. S3B ).
IM TRANSPLANTATION AND GUT-LIVER AXIS: HFGFD INDUCED A SELECTIVE ACTIVATION OF INTESTINAL FARNESOID X RECEPTOR THAT WAS PARTIALLY REVERSED AFTER RESTORATION OF A HEALTHY IM
After 8 weeks of HFGFD, the early-NASH model was characterized by a significant increase in ileum mRNA expression of canonic intestinal farnesoid X receptor (FXR) target genes (fibroblast growth factor-15 and small heterodimer partner) compared with controls (Fig. 6A) . However, when the status of the (E) Western blot analysis of intrahepatic markers of endothelial dysfunction. Bar diagrams show the quantification of P-AKT and P-eNOS using glyceraldehyde 3-phosphate dehydrogenase as a loading control and normalized to the HFGFD-Atr group. Representative western blots are shown below. Data represent mean 6 standard error of the mean; *P < 0.05 versus CD. (F) Relative mRNA expression of a-SMA and COL1A1 by quantitative RT-PCR, expressed as fold change. b-Actin was used as an endogenous control, and results were normalized to the CD-Atr group. Abbreviations: CD, Control diet; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H/E, hematoxylin and eosin; HFGFD, high-fat, high-glucose/fructose diet; NAS, NAFLD activity score; n.s., not significant. hepatic FXR pathway was assessed, no changes were observed between groups (Fig. 6B) . Notably, transplantation of HFGFD-fed rats with a healthy IM (HFGFD-Tr) induced a reduction of fibroblast growth factor-15 intestinal mRNA expression to levels comparable to CD controls. FXR mRNA expression remained unaltered in all transplanted groups (Fig.  6C) , and no changes were observed in the FXR pathway in liver (Fig. 6D) . The intestinal expression of TGR5 and its target gene glucagon-like peptide-1 was not substantially modified by IM transplantation (Supporting Fig. S4A,B) .
Finally, the expression of genes encoding for tight junction proteins (zonula occludens-1 and occludin) was assessed in ileum (Supporting Fig. S4C ). At baseline, mRNA expression of zonula occludens-1 and occludin was similar between the NASH model and controls. Decontamination and IM transplantation produced a significant increase in mRNA expression of zonula occludens-1 compared to nontransplanted controls, which was similar in all transplanted groups, suggesting that these changes were likely due to the decontamination procedure.
Discussion
In the present proof-of-concept experimental study, we show that the IM may play a key role in the pathogenesis of PH in NASH, independently of liver fibrosis. We observed, in a newly developed preclinical rat model of diet-induced NASH with PH and intestinal dysbiosis, that the restoration of a healthy IM (by means of fecal transplantation from eubiotic rats) was able to normalize PP. The resolution of PH was due to nonstructural changes, namely a significant decrease in intrahepatic vascular resistance which was associated with an amelioration of endothelial dysfunction. Our results suggest that the amelioration of endothelial dysfunction observed after healthy IM transplantation occurs through restoration of the sensitivity to insulin of the hepatic Akt-dependent eNOS signaling pathway.
Ongoing efforts to develop effective drug therapies in NASH are hindered by the current need to focus on changes in fibrosis as the main endpoint in clinical trials, which requires long follow-up times. The identification of specific biomarkers for NASH that appear early in the disease, respond sensitively to therapies, and correlate with clinical outcomes will accelerate drug development and remains one of the main challenges in the field. In this regard, PH and endothelial dysfunction can be present at very early stages of NASH, even before the activation of profibrotic and proinflammatory processes. (3, 7, 8, 17) This opens the possibility of considering liver endothelial dysfunction and PH in NASH not only as therapeutic targets but also as sensitive potential biomarkers to monitor disease progression and response to therapies.
However, the exact mechanisms regulating liver endothelial dysfunction in NASH are incompletely understood. In the present study, we investigated the potential role of IM in the regulation of PH in NASH. To address this question, we first needed to develop and characterize an adequate animal model of diet-induced NASH with PH and dysbiosis, reproducing the key phenotypic features of early NASH. Genetic NASH models lack the characteristic IM found in NASH patients. Most available diet-induced NASH models have not been characterized in terms of PH and related mechanisms. Previous experimental efforts to study PH in NASH have used models obtained through nonphysiological dietary manipulations or lacking either IR (6, 7) or full NASH histologic features. (8) The only available report to date focusing on the link between IM and PH used a portal-vein ligation model in germ-free mice lacking NASH metabolic and histologic features. (13) From this perspective, our model has several strengths. All animals developed IR and full histologic NASH (steatosis, ballooning, and inflammation) in a short period of time (8 weeks) . These are important advantages of etiology-dependent NASH models over classic PH experimental models. The 8-week dietary intervention induced PH to a degree similar to an experimental 16G portal-vein ligation (14) and the characteristic molecular profile of liver insulin resistance and endothelial dysfunction. Finally, the 8-week HFGFD intervention induced a marked and etiologydependent dysbiosis, similar to what is observed in NASH patients. (18) For studies focusing on the role of IM, this is another critical advantage of diet-induced NASH models over genetic models of NASH or classic PH models. The dietary intervention, however, was not able to induce a relevant fibrotic response in the liver in 8 weeks. This obviously renders the 8-week model inadequate to study fibrosis mechanisms in NASH, response to antifibrotic drugs, or the regulation of PH in the context of cirrhosis. However, this same feature makes the model ideal to study the role of endothelial dysfunction in PH within the specific etiologic context of NASH and without the overlap of intrahepatic structural components (fibrosis, angiogenesis) or the extrahepatic hemodynamic perturbations characteristic of classic PH experimental models.
Once the model was developed and characterized, we opted for a whole fecal transplantation experiment to provide proof-of-concept evidence about the role of IM in the regulation of the etiology-dependent phenotype. Fecal transplantation experiments clearly lack the specificity and precision of more directed microbiological or mechanistic studies, but as a starting point they provide high-quality evidence on the pathogenic importance of IM as a whole and thus have become paradigmatic in microbiota science. Regarding the importance of IM in the pathogenesis of liver disease, it has been shown that IM is key to modulating steatosis, inflammation, and even fibrosis in different etiologic models of liver disease. (9, 11, 12, 19) We herein report on the importance of IM in the regulation of PH in an etiologic model of liver disease. In their seminal work, Moghadamrad and coworkers provided evidence that IM was necessary for a portal vein ligation to induce PH in a germ-free mouse model. (13) However, the unique characteristics of germ-free models and the absence of intrahepatic abnormalities induced by portal vein ligation are hard to extrapolate to the specific context of NASH, in which other factors (such as endothelial dysfunction, IR, or a specific etiologydependent dysbiosis) (8, 17) have been shown to play a key role in the regulation of PH.
Our results suggest that the effect of IM on the amelioration of PH is mediated by an improvement of insulin-dependent regulation of liver endothelial function. In our study, IM transplantation did not induce relevant structural intrahepatic changes in inflammation and fibrosis. The liver endothelial phenotype, however, was markedly changed after restoring a eubiotic IM. It has been reported that the IM is able to modulate energy metabolism, either directly (through bacteria-derived compounds) (20) or indirectly (through interaction with the immune system and/or intestinal cells) (21) ; and restoration of a eubiotic IM has been proven to induce an amelioration of IR in preclinical models (22, 23) of metabolic disease as well as in patients. (20) It has also been shown that eNOS activation is highly dependent on the responsiveness to insulin of the insulin receptor substrate-phosphoinositide 3-kinase-Akt pathway, which is altered in NASH. (17) Besides, it is known that intrahepatic levels of eNOS are closely correlated to ex vivo intrahepatic vasodilating responsiveness. (8, 17, (24) (25) (26) In our model, HFGFD rats presented a significant decrease of PeNOS and P-Akt compared to controls, and these levels were normalized after eubiotic IM transplantation, indicating a restoration of intrahepatic insulin sensitivity with the consequent up-regulation of the Aktdependent activation of eNOS. These results highlight, on the one hand, the importance of endothelial function over fibrosis, inflammation, or extrahepatic factors in the regulation of PH in the early stages of NASH and, on the other hand, the critical role of IM in the regulation of hepatic insulin sensitivity, endothelial function, and PH in the specific context of NASH.
Finally, we explored potential mechanistic explanations of how IM can remotely control liver endothelial function. In this regard, the FXR axis has been shown to be key at modulating the gut-liver interaction and is currently the subject of intense research as a therapeutic target in NASH. (19, 27, 28) In addition, FXR agonism has been proven to ameliorate PH and endothelial dysfunction in toxic and cholestatic cirrhosis models. (29) In our model of early NASH, we observed a selective activation of intestinal FXR activity that was partially reversed by eubiotic IM transplantation. This is in line with previous studies showing that selective inhibition of intestinal FXR improves IR and NAFLD in mice. (19) It has been suggested that the IM may influence FXR through the metabolism of bile acids. Thus, it could be speculated that, in our study, IM transplantation may have modified bile acid composition in the gut, decreasing the selective activation of intestinal FXR, which in turn may affect endothelial function either directly or indirectly by improving IR. This hypothesis would require further directed metabolomic studies. We did not look directly to other potential modulators of the effect of IM in the liver, such as bacterial translocation, direct bacterial products, or changes in inflammasome status in our model. However, our results suggest that molecular markers of gut barrier integrity are unrelated to the change in IM. More studies would be needed to clarify the precise mechanisms of these effects.
The main strengths and limitations of the model and the whole fecal transplantation approach have been discussed above. Another obvious limitation of IM transplantation is that the beneficial effects are unlikely to extend in time. We obtained our results shortly after IM transplantation. It is expected that the eubiotic IM would drift back to dysbiosis under the same HFGFD that induces our model phenotype. We believe that the value of the IM transplantation in our study should be considered as proof-of-concept of the effect of IM on PH in NASH, rather than a potential long-term therapeutic option.
Our work opens new therapeutic perspectives to develop next-generation microbiome-based diagnostic and therapeutic strategies for PH in NASH. Future approaches should focus on the development of humanized models with long-term IM transplants, the identification of IM communities exhibiting antiendothelial dysfunction properties, and further characterization of the mechanisms using new technological advances such as metagenomics and metabolomics.
